BioCentury
ARTICLE | Clinical News

APL-130277: Preliminary Phase III data

August 8, 2016 7:00 AM UTC

Preliminary data from 92 evaluable PD patients in the open-label, dose-escalation portion of the U.S. Phase III CTH-300 trial showed that sublingual APL-130227 improved mean MDS-UPDRS Part III score f...